Xeris Biopharma's August 6, 2026 update showed second-quarter revenue rising to US$92.1 million while net loss widened to US$31.1 million, and the company tightened its full-year 2026 total revenue guidance to US$385 million–US$390 million.
Alongside record quarterly revenue, Xeris highlighted strong Recorlev momentum, full retirement of its convertible notes, and progress toward a Phase III start for XP-8121, reshaping its operational profile.
We'll now examine how this tighter 2026 revenue guidance range influences Xeris Biopharma's broader investment narrative and future expectations.
Outshine the giants: these 17 early-stage AI stocks could fund your retirement.
To own Xeris Biopharma, you need to believe its focused endocrine portfolio and XP-8121 pipeline can ultimately support a sustainable, profitable business. The latest update, with record Q2 revenue of US$92.1 million and tighter 2026 guidance at US$385 million to US$390 million, reinforces revenue visibility but also highlights execution risk as net losses widened. In the near term, progress toward XP-8121 Phase III remains a key catalyst, while rising expenses and ongoing losses are the most immediate financial risk.
Among recent developments, the full retirement of Xeris's convertible notes stands out as especially relevant here. Reducing this layer of debt simplifies the balance sheet at a time when the company is still posting net losses, and it may give management more flexibility as they fund XP-8121 and support Recorlev growth. For investors watching catalysts, this cleaner capital structure sits alongside the updated guidance as part of the evolving risk reward profile.
Yet behind the strong revenue guide, investors should still be aware of the growing gap between sales momentum and widening net losses…
Read the full narrative on Xeris Biopharma Holdings (it's free!)
Xeris Biopharma Holdings' narrative projects $440.9 million revenue and $84.8 million earnings by 2028. This requires 21.5% yearly revenue growth and a $116.8 million earnings increase from $-32.0 million today.
Uncover how Xeris Biopharma Holdings' forecasts yield a $11.14 fair value, a 30% upside to its current price.
Before this earnings beat and tighter guidance, the most optimistic analysts were assuming about US$602 million of revenue and US$163 million of earnings by 2029, so you may find their much rosier view of margin expansion and cash generation quite different from the more cautious focus on cost pressure and concentration risk that this latest report brings into sharper focus.
Explore 3 other fair value estimates on Xeris Biopharma Holdings - why the stock might be worth over 2x more than the current price!
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
A great starting point for your Xeris Biopharma Holdings research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
Our free Xeris Biopharma Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Xeris Biopharma Holdings' overall financial health at a glance.
Every day counts. These free picks are already gaining attention. See them before the crowd does:
Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
Uncover the next big thing with 18 elite penny stocks that balance risk and reward.
The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include XERS.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]